Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers

Overview

Journal Patient Prefer Adherence

Date 2022 May 27

PMID 35619589

Authors

Katy Gallop

Sarah Acaster

Jane de Vries

Richard Browne

Robert Ryan

Sarah Baker

George Du Toit

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to estimate utility values for health states relating to oral immunotherapy (OIT) for peanut allergy (PA), for children with PA and their caregivers.

Patients And Methods: Two methods were used: an online survey and structured interviews. Both methods assessed current utility/untreated PA (health-related quality of life, HRQoL) and HRQoL in different health states: "up-dosing phase of treatment", "maintenance phase" and "able to tolerate 6-8 peanuts if accidentally ingested". The survey was conducted in individuals with and without experience of OIT; data collected included the EQ-5D-Y (child states) and EQ-5D-5L (caregiver states).

Results: In total, 100 caregivers and 38 adolescents completed the treatment-naïve survey, a separate sample of 50 caregivers participated in structured interviews. Seven caregivers and two adolescents with experience of OIT for PA completed the survey. Data from the three samples were pooled, the mean utility values were untreated PA: 0.796 (child), 0.855 (caregiver); up-dosing: 0.711 (child), 0.806 (caregiver); maintenance: 0.821 (child), 0.849 (caregiver), tolerate 6-8 peanuts: 0.859 (child), 0.884 (caregiver). The results show a gain in utility of 0.063 for children and 0.029 for caregivers between the untreated and tolerate 6-8 peanuts health states.

Conclusion: This study is the first to assess utilities relating to OIT for PA. The results show the potential benefit of OIT for individuals with PA and their caregivers and provide values for use in cost-effectiveness evaluation.

Citing Articles

Estimating the Health-Related Quality of Life Benefit of Prophylactic Treatment for COVID-19 in Immunocompromised People: A Multimethod Valuation Study.

Gallop K, Hall R, Watt M, Squirrell D, Branscombe N, Arnetop S J Health Econ Outcomes Res. 2024; 11(2):20-28.

PMID: 39071729 PMC: 11276479. DOI: 10.36469/001c.120605.

References

Bock S, Munoz-Furlong A, Sampson H . Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001; 107(1):191-3. DOI: 10.1067/mai.2001.112031. View

Bollinger M, Dahlquist L, Mudd K, Sonntag C, Dillinger L, McKenna K . The impact of food allergy on the daily activities of children and their families. Ann Allergy Asthma Immunol. 2006; 96(3):415-21. DOI: 10.1016/S1081-1206(10)60908-8. View

Weinstein M, Torrance G, McGuire A . QALYs: the basics. Value Health. 2009; 12 Suppl 1:S5-9. DOI: 10.1111/j.1524-4733.2009.00515.x. View

DunnGalvin A, Gallop K, Acaster S, Timmermans F, Regent L, Schnadt S . APPEAL-2: A pan-European qualitative study to explore the burden of peanut-allergic children, teenagers and their caregivers. Clin Exp Allergy. 2020; 50(11):1238-1248. PMC: 7780296. DOI: 10.1111/cea.13719. View

Lamb A, Murray A, Lovett R . The Challenges of Measuring and Valuing Quality of Life in Preschool Children: A Retrospective Review of NICE Appraisals. Children (Basel). 2021; 8(9). PMC: 8464668. DOI: 10.3390/children8090765. View

Acaster S, Gallop K, de Vries J, Ryan R, Vereda A, Knibb R . Peanut allergy impact on productivity and quality of life (PAPRIQUA): Caregiver-reported psychosocial impact of peanut allergy on children. Clin Exp Allergy. 2020; 50(11):1249-1257. DOI: 10.1111/cea.13727. View

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

van Hout B, Janssen M, Feng Y, Kohlmann T, Busschbach J, Golicki D . Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012; 15(5):708-15. DOI: 10.1016/j.jval.2012.02.008. View

Scott L, Jones B, Berni T, Berni E, de Vries J, Currie C . Evaluation of the epidemiology of peanut allergy in the United Kingdom. Expert Rev Clin Immunol. 2019; 15(12):1333-1339. DOI: 10.1080/1744666X.2020.1693264. View

10.

King R, Knibb R, Hourihane J . Impact of peanut allergy on quality of life, stress and anxiety in the family. Allergy. 2008; 64(3):461-8. DOI: 10.1111/j.1398-9995.2008.01843.x. View

11.

Golding M, Gunnarsson N, Middelveld R, Ahlstedt S, Protudjer J . A scoping review of the caregiver burden of pediatric food allergy. Ann Allergy Asthma Immunol. 2021; 127(5):536-547.e3. DOI: 10.1016/j.anai.2021.04.034. View

12.

Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N . Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010; 19(6):875-86. PMC: 2892611. DOI: 10.1007/s11136-010-9648-y. View

13.

Acaster S, Gallop K, de Vries J, Marciniak A, Ryan R, Vereda A . Psychosocial and productivity impact of caring for a child with peanut allergy. Allergy Asthma Clin Immunol. 2020; 16:83. PMC: 7517656. DOI: 10.1186/s13223-020-00477-3. View

14.

Lopez-Bastida J, Lopez-Siguero J, Oliva-Moreno J, Vazquez L, Aranda-Reneo I, Reviriego J . Health-related quality of life in type 1 diabetes mellitus pediatric patients and their caregivers in Spain: an observational cross-sectional study. Curr Med Res Opin. 2019; 35(9):1589-1595. DOI: 10.1080/03007995.2019.1605158. View

15.

DunnGalvin A, Blumchen K, Timmermans F, Regent L, Schnadt S, Podesta M . APPEAL-1: A multiple-country European survey assessing the psychosocial impact of peanut allergy. Allergy. 2020; 75(11):2899-2908. PMC: 7689848. DOI: 10.1111/all.14363. View

16.

Whitehead S, Ali S . Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010; 96:5-21. DOI: 10.1093/bmb/ldq033. View

17.

Protudjer J, Jansson S, Heibert Arnlind M, Bengtsson U, Kallstrom-Bengtsson I, Marklund B . Household costs associated with objectively diagnosed allergy to staple foods in children and adolescents. J Allergy Clin Immunol Pract. 2015; 3(1):68-75. DOI: 10.1016/j.jaip.2014.09.021. View

18.

Shaker M, Greenhawt M . Peanut allergy: Burden of illness. Allergy Asthma Proc. 2019; 40(5):290-294. DOI: 10.2500/aap.2019.40.4240. View

19.

Hill H, Rowen D, Pennington B, Wong R, Wailoo A . A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents. Value Health. 2020; 23(7):907-917. DOI: 10.1016/j.jval.2020.02.011. View

20.

Dolan P . Modeling valuations for EuroQol health states. Med Care. 1997; 35(11):1095-108. DOI: 10.1097/00005650-199711000-00002. View